Delivery Order 36F79721D0166-36C26024F0270
Award Date 3/12/24
Potential Completion Date 3/11/25
Potential Value $388K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Earth City, MO 63045, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This federal contract award is for ORLADEYO EMERGENT, a pharmaceutical product, to Biocryst Pharmaceuticals Inc. as the prime contractor. The contract has a ceiling value of $29,649.88 and is a delivery order under Biocryst's Federal Supply Schedule (FSS) contract (36F79721D0166) for Pharmaceuticals and Drugs with the Department of Veterans Affairs (VA). Biocryst is a biotechnology company that specializes in the development of small molecule drugs for rare diseases, and it primarily supplies...
- This federal contract award to Biocryst Pharmaceuticals Inc. is for the delivery of the pharmaceutical product ORLADEYO (berotralstat) to the Veterans Integrated Service Network 20 (VISN 20), a civilian healthcare agency under the Department of Veterans Affairs (VA). The fixed-price delivery order has a ceiling value of $360,000.00 and a period of performance through September 30, 2026. The contract is not set aside and is awarded under Biocryst's existing Federal Supply Schedule (FSS) contract,...
- This federal contract award was made by the Veterans Integrated Service Network 20 (VISN 20), a civilian agency, to Biocryst Pharmaceuticals Inc., a biotechnology company specializing in rare disease pharmaceuticals. The $379,939.32 firm fixed-price delivery order contract is for the supply of BEROTRALSTAT HCL 150MG CAP,ORAL (ORLADEYO), a medication used to treat hereditary angioedema. The contract has an ultimate completion date of September 30, 2025 and was awarded on October 1, 2024. The...
- This is a delivery order contract awarded to Biocryst Pharmaceuticals Inc., a biotechnology company that specializes in developing small molecule drugs for rare diseases. The contract is valued at $201,721.59 and has an ultimate completion date of October 4, 2024. The contract is for the delivery of ORLADEYO 150MG CAPS, a pharmaceutical product used to treat hereditary angioedema. The contract was awarded by the U.S. Department of Veterans Affairs (VA), specifically the Veterans Integrated...
- This federal contract award is a $69,388,368.75 delivery order to Biocryst Pharmaceuticals Inc. for the supply of PERAMIVIR (RAPIVAB 200MG/20ML (10MG/ML INJ SOLN)) pharmaceutical products. The contract was awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency within the Department of Health and Human Services. The contract is a delivery order under Biocryst's existing Federal Supply Schedule (FSS-61-IB) contract for Pharmaceuticals and Drugs, with a...
- Biocryst Pharmaceuticals, Inc. was awarded a $56,670.76 firm fixed price delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 20. The contract calls for the delivery of berotralstat to Roseburg, Oregon with a period of performance concluding on January 19, 2024. No set-aside designation was applied to this award issued against GSA Schedule 61-IB for pharmaceutical...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 20 awarded a $113,440.80 delivery order to Biocryst Pharmaceuticals, Inc. under the firm fixed price Pharmaceuticals and Drugs Federal Supply Schedule contract. This order is for the delivery of BEROTRALSTAT HCL 150MG CAP,ORAL BULK to the place of performance in Durham, North Carolina by May 31, 2023. The contract was awarded on June 1, 2022 and has no set-aside designation. Biocryst...
- This federal contract award is for the delivery of the pharmaceutical product KRYSTEXXA 8MG to the Department of Veterans Affairs (VA) Veterans Health Administration. The $2,425.46 firm-fixed price delivery order was awarded to the prime contractor Vifor (International) AG, a global biotechnology company that provides pharmaceuticals and drugs through its Federal Supply Schedule contract. The contract is associated with the VA's Pharmaceuticals and Drugs (FSS-61-IB) Schedule, and the delivery...
- This contract award is for the delivery of KRYSTEXXA 8MG, a specialty pharmaceutical product, to the United States Department of Veterans Affairs (VA). The contract, valued at $37,268.88, is a firm fixed-price delivery order placed by the VA's Veterans Integrated Service Network 5 (VISN 5) against the prime contractor Horizon Therapeutics USA, Inc.'s Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). Horizon Therapeutics USA, Inc. is a global biotechnology...
- This federal contract award, valued at $1,375.85, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under a broader Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products...